Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Total Non-Current Liabilities (2020 - 2024)

Kymera Therapeutics (KYMR) has disclosed Total Non-Current Liabilities for 5 consecutive years, with $142.4 million as the latest value for Q4 2024.

  • For Q4 2024, Total Non-Current Liabilities fell 21.22% year-over-year to $142.4 million; the TTM value through Dec 2024 reached $142.4 million, down 21.22%, while the annual FY2024 figure was $142.4 million, 21.22% down from the prior year.
  • Total Non-Current Liabilities hit $142.4 million in Q4 2024 for Kymera Therapeutics, down from $180.8 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $203.2 million in Q4 2020 and bottomed at $112.7 million in Q4 2022.
  • Average Total Non-Current Liabilities over 5 years is $153.5 million, with a median of $149.0 million recorded in 2023.
  • Year-over-year, Total Non-Current Liabilities dropped 29.14% in 2022 and then soared 60.37% in 2023.
  • Kymera Therapeutics' Total Non-Current Liabilities stood at $203.2 million in 2020, then dropped by 28.05% to $146.2 million in 2021, then decreased by 22.89% to $112.7 million in 2022, then skyrocketed by 60.37% to $180.8 million in 2023, then fell by 21.22% to $142.4 million in 2024.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods came in at $142.4 million, $180.8 million, and $156.8 million for Q4 2024, Q4 2023, and Q3 2023 respectively.